Company type | Subsidiary |
---|---|
Industry | Pharmaceuticals |
Founded | 1997 |
Headquarters | Chippenham, England, UK |
Number of locations | 5 (2019) |
Key people | Bruno Angelici, Chairman Michael Austwick, (CEO) |
Revenue | £190.6 million (2020) [1] |
£132.8 million (2020) [1] | |
£122.4 million (2020) [1] | |
Number of employees | 450 (2021) [2] |
Parent | Philip Morris International |
Website | www |
Vectura Group Limited is a British pharmaceuticals company based in Chippenham, England which develops inhaled medicines and makes inhaler devices. The company was listed on the London Stock Exchange until it was acquired by Philip Morris International in September 2021.
The company was formed in 1997 at the University of Bath as a start-up pharmaceuticals business. [3] In 1999 it acquired Co-ordinated Drug Development and the Centre for Drug Formulation Studies. [4] The company moved from the university campus to a site at Chippenham in 2002. [3] In 2004 it was listed on the Alternative Investment Market. [3] In 2006 it acquired Innovata Biomed plc, another developer of pulmonary products, [5] and then moved onto the full list of the London Stock Exchange. [4] It acquired Activaero, a German manufacturer in the same sector, for £108 million in March 2014. [6] In June 2016 Vectura completed a £441 million merger with Skyepharma, a maker of devices such as asthma inhalers; it was announced that the merged company would continue to be known as Vectura. [7]
The former Skyepharma manufacturing plant at Lyon, France, makes various oral products including tablets. After Vectura decided to concentrate on inhaled products, in June 2021 the company supported a buy-out of the site by its management, with finance from Bpifrance. [8]
In July 2021, American tobacco company Philip Morris International made an offer to buy Vectura Group for £1 billion. [9] The Carlyle Group, an American private equity firm, also submitted an offer which was £44m lower. [10] The board subsequently accepted the offer from Philip Morris International [11] and, in September 2021, the company confirmed that circa 75% of shareholders had supported the takeover. [12]
The takeover by Philip Morris was widely condemned. [13] [14] Because Vectura is now part of the tobacco industry, the company, and people who work for it or in collaboration with it, are subject to policies that exclude the tobacco industry. [15]
The British Thoracic Society made the following statement:
Vectura, a company that for over 20 years has worked to treat lung disease, is now part of the tobacco industry. This is inappropriate, unethical and should have been prevented. The society’s policy in relation to the tobacco industry remains clear. [13]
The Forum of International Respiratory Societies (FIRS) took the following position:
We give official notice that our organizations and members cannot condone new interactions and links with any company wholly owned by a tobacco company such as Phillip Morris International. This is in accordance with our rules, ethical codes, and the World Health Organization’s Framework Convention on Tobacco Control (the UN Tobacco Control Treaty) guidance. [16]
The American Thoracic Society stated:
ATS prohibits tobacco companies and those who have received funding from tobacco companies from involvement with the ATS in a number of ways, from publishing in ATS journals, to presenting at our international conference. We believe it’s critical that a separation be maintained between tobacco companies and respiratory health groups. These polices, based on the extensive evidence of misconduct over many years by the tobacco industry, reflect the total lack of confidence we have in any claims from the tobacco industry of efforts to improve health. [17]
Vectura is a developer of inhaled therapies for the treatment of respiratory diseases. [18] Since 2019 it has operated as a contract development and manufacturing organization (CDMO), helping other companies bring inhaled medicines to market. [3]
The headquarters and development facility at Chippenham, on a mixed industrial site on the outskirts of the town, employs around 250 as of 2022 [update] . [19] There are also development sites at Cambridge, Muttenz (Basel, Switzerland) and Gauting (Germany). [3] There are plans for a new research & development building at the Bristol and Bath Science Park, not far from Chippenham, which could open in 2025. [20]
A cigarette is a narrow cylinder containing a combustible material, typically tobacco, that is rolled into thin paper for smoking. The cigarette is ignited at one end, causing it to smolder; the resulting smoke is orally inhaled via the opposite end. Cigarette smoking is the most common method of tobacco consumption. The term cigarette, as commonly used, refers to a tobacco cigarette, but the word is sometimes used to refer to other substances, such as a cannabis cigarette or an herbal cigarette. A cigarette is distinguished from a cigar by its usually smaller size, use of processed leaf, and paper wrapping, which is typically white.
The tobacco industry comprises those persons and companies who are engaged in the growth, preparation for sale, shipment, advertisement, and distribution of tobacco and tobacco-related products. It is a global industry; tobacco can grow in any warm, moist environment, which means it can be farmed on all continents except Antarctica.
Altria Group, Inc. is an American corporation and one of the world's largest producers and marketers of tobacco, cigarettes, and related products. It operates worldwide and is headquartered in Henrico County, Virginia, just outside the city of Richmond.
British American Tobacco p.l.c. (BAT) is a British multinational company that manufactures and sells cigarettes, tobacco and other nicotine products. The company, established in 1902, is headquartered in London. As of 2021, it is the largest tobacco company in the world based on net sales.
The Financial Times Stock Exchange 100 Index, also called the FTSE 100 Index, FTSE 100, FTSE, or, informally, the "Footsie", is a stock market index of 100 of the most highly capitalised blue chip companies listed on the London Stock Exchange.
The Japan Tobacco Inc. (JT) is a Japanese diversified tobacco company. It was established in 1985 as a tokushu gaisha that inherited the right to monopolize and manufacture cigarettes from the Japan Tobacco and Salt Public Corporation and required the government to hold at least 50% of its shares. In addition to tobacco, JT diversified its businesses, establishing the pharmaceutical research institute in 1993 and making a full-scale entry into the food and beverage industry in 1998. In 2008, it acquired the food manufacturer Katokichi, now TableMark, as a wholly-owned subsidiary, integrating its food business.
Swedish Match AB is a Swedish multinational tobacco company headquartered in Stockholm. The company manufactures snus, nicotine pouches, moist snuff, tobacco- and nicotine-free pouch products, chewing tobacco, chew bags, tobacco bits, cigars, matches, lighters, and other fire products with operations in Sweden, Denmark, the United States, the Dominican Republic, Brazil, the Netherlands, and the Philippines. The company's origins can be traced back to 1868, and Ivar Kreuger. Swedish Match has played an important part in Sweden's industrial development.
Passive smoking is the inhalation of tobacco smoke, called passive smoke, secondhand smoke (SHS) or environmental tobacco smoke (ETS), by individuals other than the active smoker. It occurs when tobacco smoke diffuses into the surrounding atmosphere as an aerosol pollutant, which leads to its inhalation by nearby bystanders within the same environment. Exposure to secondhand tobacco smoke causes many of the same diseases caused by active smoking, although to a lower prevalence due to the reduced concentration of smoke that enters the airway.
Nicotine replacement therapy (NRT) is a medically approved way to treat people with tobacco use disorder by taking nicotine through means other than tobacco. It is used to help with quitting smoking or stopping chewing tobacco. It increases the chance of quitting tobacco smoking by about 55%. Often it is used along with other behavioral techniques. NRT has also been used to treat ulcerative colitis. Types of NRT include the adhesive patch, chewing gum, lozenges, nose spray, and inhaler. The use of multiple types of NRT at a time may increase effectiveness.
An inhaler is a medical device used for delivering medicines into the lungs through the work of a person's breathing. This allows medicines to be delivered to and absorbed in the lungs, which provides the ability for targeted medical treatment to this specific region of the body, as well as a reduction in the side effects of oral medications. There are a wide variety of inhalers, and they are commonly used to treat numerous medical conditions with asthma and chronic obstructive pulmonary disease (COPD) being among the most notable.
Kretek are unfiltered cigarettes of Indonesian origin, made with a blend of tobacco, cloves, and other flavors. The word "kretek" itself is an onomatopoetic term for the crackling sound of burning cloves.
Philip Morris International Inc. (PMI) is an American multinational tobacco company, with products sold in over 180 countries. The most recognized and best selling product of the company is Marlboro. Philip Morris International is often referred to as one of the companies comprising Big Tobacco.
A metered-dose inhaler (MDI) is a device that delivers a specific amount of medication to the lungs in the form of a short burst of aerosolized medicine that is usually self-administered by the patient via inhalation. It is the most commonly used delivery system for treating asthma, chronic obstructive pulmonary disease (COPD) and other respiratory diseases. The medication in a metered dose inhaler is most commonly a bronchodilator, corticosteroid or a combination of both for treating asthma and COPD. Other medications less commonly used but also administered by MDI are mast cell stabilizers, such as cromoglicate or nedocromil.
The American Thoracic Society (ATS) is a nonprofit organization focused on improving care for pulmonary diseases, critical illnesses and sleep-related breathing disorders. It was established in 1905 as the
An electronic cigarette (e-cigarette) or vape is a device that simulates tobacco smoking. It consists of an atomizer, a power source such as a battery, and a container such as a cartridge or tank. Instead of smoke, the user inhales vapor. As such, using an e-cigarette is often called "vaping". The atomizer is a heating element that vaporizes a liquid solution called e-liquid, which quickly cools into an aerosol of tiny droplets, vapor and air. The vapor mainly comprises propylene glycol and/or glycerin, usually with nicotine and flavoring. Its exact composition varies, and depends on several things including user behavior.
A heated tobacco product (HTP) is a tobacco product that heats the tobacco at a lower temperature than conventional cigarettes. These products contain nicotine, which is a highly addictive chemical. The heat generates an aerosol or smoke to be inhaled from the tobacco, which contains nicotine and other chemicals. HTPs may also contain additives not found in tobacco, including flavoring chemicals. HTPs generally heat tobacco to temperatures under 600 °C (1100 °F), a lower temperature than conventional cigarettes.
Iqos is a line of heated tobacco and electronic cigarette products manufactured by Philip Morris International (PMI). It was first introduced in November 2014 in Japan and Italy. Most of the IQOS products are devices that heat tobacco without burning it.
The Foundation for a Smoke-Free World is an organization focused on smoking harm reduction founded in 2017.
Mundipharma International Limited is a British multinational research-based pharmaceutical company owned by members of the Sackler family with locations in United Kingdom, Canada, Germany, and Singapore. In Germany, Mundipharma is a subsidiary of Mundipharma International Limited and Mundipharma AG. Its global headquarters located at the Cambridge Science Park of Cambridge, England.
Kristin Carson-Chahhoud is an associate professor at the University of South Australia, heading a research group in the Adelaide Medical School. Specialising in respiratory medicine, tobacco control and management of tobacco-related illnesses, Carson aims to close the gap between clinical research trials and real-world patient care.